Liver Injury/Regeneration News

COVID-19 vaccination correlated with a decreased risk for hospitalization among patients with cirrhosis and other high-risk comorbidities, according to research presented at The Liver Meeting Digital Experience.

Among patients with cirrhosis, younger age, active tobacco use, fewer medical comorbidities and residence in the southern United States correlated with decreased rates of COVID-19 vaccination.

There was an 81% increase in alcohol-associated hepatitis admissions within the first year of the COVID-19 pandemic and resulted in a significant increase in liver transplantation, according to a presentation.

Waist circumference independently correlated with the risk for advanced fibrosis among patients with type 2 diabetes, according to a presenter at the European Association for the Study of Diabetes Annual Meeting.

Healio Gastroenterology and Hepatology presents the following report on recent stories from the Digital NAFLD Summit 2021.

Pioglitazone was safe and effective in improving liver histology among patients with nonalcoholic steatohepatitis, according to a presenter at the Digital NAFLD Summit 2021.

Researchers identified more patients with fatty liver disease using novel metabolic dysfunction-associated fatty liver disease criteria compared with nonalcoholic fatty liver disease criteria.

Researchers recommended a third SARS-CoV-2 vaccination dose for liver transplant recipients and patients with cirrhosis who have a low or absent serological response.

Women who only accessed deceased donor liver transplant had worse outcomes than men independent of existing liver disease but access to living donor LT may bridge this disparity gap women face.

Among patients hospitalized with COVID-19, liver impairment appeared within the first days of admission; virus severity also correlated with abnormality in liver function tests.